Actinium Pharmaceuticals, Inc.
AMEX:ATNMBiotechnology
Healthcare
$1.64 +15.94%
+$0.22 today
- Market cap
- $51.56M
- Beta
- 0.02
- P/E (TTM)
- 4.4
- EPS (TTM)
- $0.36
52W Low $0.74High $1.74
Volume 0.18M
Average 0.15M
Income Statement
Follow revenue through to earnings.
Revenue
$90,000.00
FY 2025 · Annual
Operating Income
-$36.25M
FY 2025 · Annual
Net Income
-$33.89M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.14M | 1.03M | 81K | 0 | 90K |
| Cost of Revenue | 524K | 0 | 0 | 811K | 0 |
| Gross Profit | 620K | 1.03M | 81K | (811K) | 90K |
| Gross Margin | 54.2% | 100.0% | 100.0% | — | 100.0% |
| Research & Development | 17.51M | 23.14M | 38.67M | 30.05M | 21.12M |
| Selling, General & Admin | 8.08M | 12M | 13.33M | 12.08M | 15.21M |
| Operating Expenses | 25.58M | 35.13M | 52M | 41.31M | 36.34M |
| Depreciation & Amortization | 524K | 699K | 790K | 811K | 821K |
| EBITDA | (24.25M) | (32.32M) | (48.03M) | (37.43M) | (33.07M) |
| EBITDA Margin | -2119.8% | -3137.7% | -59293.8% | — | -36740.0% |
| Operating Income | (24.96M) | (34.1M) | (51.92M) | (42.12M) | (36.25M) |
| Operating Margin | -2182.2% | -3311.1% | -64098.8% | — | -40274.4% |
| Interest Income | 190K | 1.09M | 3.1M | 3.88M | 2.36M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 190K | 1.09M | 3.1M | 3.88M | 2.36M |
| Income Before Tax | (24.77M) | (33.02M) | (48.82M) | (38.24M) | (33.89M) |
| Pre-Tax Margin | -2165.6% | -3205.5% | -60269.1% | — | -37652.2% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (24.77M) | (33.02M) | (48.82M) | (38.24M) | (33.89M) |
| Net Margin | -2165.6% | -3205.5% | -60269.1% | — | -37652.2% |
| EPS (Basic) | (1.20) | (1.37) | (1.83) | (1.27) | (1.09) |
| EPS (Diluted) | (1.20) | (1.37) | (1.83) | (1.27) | (1.09) |
| 20.57M | 24.14M | 26.6M | 30.07M | 31.2M | |
| 20.57M | 24.14M | 26.6M | 30.07M | 31.2M |
ATNM Earnings Waterfall · TTM
AMEX:ATNM · Revenue to Net Income
Key Ratios
EPS$0.36
Gross Margin50.0%
Net Margin-1405.3%
P/E Ratio-1.3
P/S Ratio138.9
Analysis
$35.1M of revenue converted into $11.3M of net income for the selected period. Gross margin is 50.0% and net margin is -1405.3%, showing how much revenue survives after costs and taxes. EPS is $0.36, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Oct 16, 2026 | |
| 3 | Initial statement of beneficial ownership | Oct 16, 2026 | |
| 8-K | Current report | Oct 15, 2026 | |
| DEF 14A | DEF 14A filing | Oct 15, 2026 | |
| ARS | ARS filing | Oct 15, 2026 |
How much revenue does ATNM generate?
Actinium Pharmaceuticals, Inc. (ATNM) reported $90,000.00 of revenue in fiscal 2025.
Is ATNM profitable?
Actinium Pharmaceuticals, Inc. (ATNM) reported -$33.89M of net income, with a net margin of -37652.2%.
Continue the stock analysis
Jump to another research area for this company.